Randy Acosta, Managing DirectorUSPC offers a full-service suite for our clients and aid pharmaceutical, medtech and biotech companies through all stages of growth. Our clients range from emerging startups to global market leaders across the healthcare spectrum, including private investors and established Rx brand and generic companies.
Through customized strategic guidance rooted in real-industry insights, we become trusted partners to organizations seeking solutions to complex drug development and commercialization challenges.
Over the last decade, the life sciences marketplace has witnessed unprecedented transformative innovations fueled by scientific breakthroughs, digital health advancements, and analytical capabilities. However, significant obstacles still exist in progressing from initial discovery to delivering novel therapies and technologies to improve patient lives at scale. This ‘bench-to-bedside’ journey requires overcoming complex scientific, regulatory, commercial, and healthcare access barriers that often outpace resources and internal expertise.
Operating as the subject matter expert, U.S. Pharma Consulting (USPC) charts the complex path of product development to market. The company expands real-world data to assist the patient journey, which increases market decision-makers' confidence in partnering with its clients.
The company was founded on the ethos of supporting pharma or life sciences organizations to navigate these hurdles.
“By becoming an embedded, agile extension of clients’ teams, we strive to unlock data-driven capabilities, strengthen value communication with essential healthcare stakeholders, fuel commercialization engines, and ultimately make the promise of life-changing health interventions a widespread reality for all those in need,” says Randy Acosta, Managing Director of USPC.
A pharmaceutical and medical technology consulting firm, USPC offers a wide array of strategic and operational services to help life sciences clients successfully bring their innovations to market and address the complexities of the healthcare industry. This includes product commercialization strategy, market research and analytics, patient support services, regulatory consulting and submissions, and quality systems and compliance. In all these areas, the company provides specialized expertise and AI-enabled solutions across the life sciences product development, commercialization, and market access continuum to drive efficiency, speed-to-market, and improved patient outcomes over the long-term product lifecycle. Its consulting services enable clients to make more informed strategic decisions at every phase.
By Becoming An Embedded, Agile Extension Of Clients’ Teams, We Strive To Unlock Data-Driven Capabilities, Strengthen Value Communication With Essential Healthcare Stakeholders, Fuel Commercialization Engines, And Ultimately Make The Promise Of Life-Changing Health Interventions A Widespread Reality For All Those In Need
USPC creates ‘Access for Success’ strategies for human and veterinary medicines companies through creative business approaches. The company devises strategic plans that navigate the complex web of pricing, ensuring that these vital medications are accessible to those who need them most. It understands the importance of balancing affordability with accessibility. For instance, in 2024, Express Scripts excluded 62 new brands from its main national formulary. USPC's approach involves negotiations to minimize such exclusions, ensuring that patients have access to a broader range of treatment options.
Unlike most consulting firms centered around a singular vantage point—be it payer, provider, patient, policy, or drug development—USPC brings together diverse leadership expertise spanning these key healthcare perspectives, from clinical medicine and pharmaceutical research and development (R&D) to health economics and governmental advisory roles. This convergence gives the company unmatched insight to align strategic planning with the multifaceted needs of the broader healthcare ecosystem from the start. Its consulting lens weaves together clinical, humanistic, and economic elements to drive better health outcomes.
Large pharma companies have been facing an innovation crisis—as R&D spending has climbed, new drug approvals have stagnated. Startups with cutting-edge platforms often burn through funding before finding product-market fit. USPC is on the frontier, working closely with clients to reverse concerning industry trends through trusted guidance grounded in experience. The company provides direction to make bold decisions that progress high-potential therapies while avoiding common pitfalls. With patient priorities at the center, it believes consulting is as much about knowledge sharing as it is about igniting human capital to bring innovations to life.
